---

Management of Cervical Intraepithelial Neoplasia (CIN)

A Comprehensive Reference for Gynecological Oncologists

---

1. PATHOLOGICAL CLASSIFICATION & NATURAL HISTORY

Colposcopic appearance of CIN 2 (HPV/CIN 2 white lesion with surface spicules):

Table 1: CIN Classification, Histology & Natural History

Key Biology: CIN originates at the squamocolumnar junction (SCJ) in the transformation zone. HPV-16 is the most common type in both CIN 2-3 and invasive cancer. Oncogenic transformation requires E6/E7 oncoprotein expression. - Berek & Novak's Gynecology, p. 834

---

2. OVERVIEW: ASCCP 2019/2025 RISK-BASED MANAGEMENT FRAMEWORK

• Extended HPV genotyping now integrated into management (HPV 16/18 vs. other HR types vs. HPV 45/33/58/31, etc.)
• p16/Ki-67 Dual Stain (DS) incorporated as triage tool (April 2024 guideline)
• Self-collected vaginal HPV specimens now acceptable (April 2025 guideline)
• Adjuvant HPV vaccination at time of treatment now formally recommended by ASCCP (December 2025)

---

3. COLPOSCOPY: THE GATEWAY TO MANAGEMENT

Indications for Colposcopy (ASCCP 2019/2025)

Colposcopy Quality Criteria (IFCPC 2011 Terminology)

---

4. MANAGEMENT FLOWCHARTS

Flowchart 1: CIN 1 Management

CIN 1 (LSIL)
├── Observation PREFERRED (regression 60-85%)
│   ├── Co-test (cytology + HPV) at 12 months
│   │   ├── Both negative → Co-test in 3 years → Routine screening
│   │   ├── HPV positive, cytology negative → Colposcopy
│   │   └── Cytology ≥ ASC (any HPV) → Manage per ASCCP guideline
│   └── If CIN 1 persists ≥ 2 years
│       ├── Continue surveillance (acceptable), OR
│       └── Treatment (ablation or excision if TZ visible)
└── NEVER treat CIN 1 as initial management

Flowchart 2: CIN 1 Post-HSIL/AGC-NOS Cytology

CIN 1 preceded by HSIL or AGC-NOS
├── Review of all material (cytology + colposcopy + biopsy)
├── If unsatisfactory colposcopy → Diagnostic excisional procedure
├── Repeat cytology + colposcopy at 6 months
│   ├── Negative x2 → Routine screening
│   ├── HSIL at any repeat → Diagnostic excision
│   └── No change on biopsy → Either observation OR diagnostic excision

Flowchart 3: CIN 1 Post-Treatment Surveillance (co-testing)

Flowchart 4: CIN 2 & CIN 3 Management

CIN 2 / CIN 3 Confirmed on Biopsy
│
├── SPECIAL POPULATIONS (manage differently):
│   ├── Age 21-24 years → Observation acceptable for CIN 2 (not CIN 3)
│   ├── PREGNANCY → Defer treatment; repeat colposcopy q12 weeks; treat postpartum
│   └── Immunocompromised → Treatment recommended regardless of grade
│
├── Satisfactory Colposcopy (TZ fully visible)?
│   ├── YES → Excision OR Ablation of transformation zone (either acceptable)
│   │         [See Section 5 for choice]
│   └── NO → Diagnostic excisional procedure ONLY (ablation contraindicated)
│
├── Recurrent CIN 2,3 → Diagnostic excisional procedure
│
└── POST-TREATMENT FOLLOW-UP:
    ├── Co-test (cytology + HPV) at 6 months AND 12 months
    ├── Negative x2 → Annual co-test for 3 years → Return to 3-year co-testing for ≥20 years
    ├── ≥ ASC on cytology → Colposcopy
    └── HPV positive → Colposcopy

---

5. CRITICAL EVALUATION OF TREATMENT OPTIONS

Table 2: Comprehensive Comparison of Treatment Modalities

Evidence for cure rates and preterm birth from: Lancet Oncology network meta-analysis, Athanasiou et al. 2022 (PMID 35835138) - 19,240 patients, 71 studies.

---

6. ABLATIVE vs. EXCISIONAL TREATMENT: DECISION FRAMEWORK

Table 3: When to Choose Ablation vs. Excision

Ablation: Absolute Contraindications (all require excision)

1. Unsatisfactory colposcopy
2. ECC positive for dysplasia or glandular abnormality
3. Histology-cytology discordance (higher cytologic grade)
4. Microinvasion suspected
5. AIS present
6. Previously treated, recurrent CIN 2/3

---

7. SPECIFIC TREATMENT PROCEDURES - DETAILED EVALUATION

7a. LEEP/LLETZ (Large Loop Excision of the Transformation Zone)

• Histologic specimen with assessable margins
• Outpatient under local anesthesia
• Cure rate 92-98%
• Simultaneous diagnostic + therapeutic ("see and treat" approach acceptable in high-risk patients)
• ECC can be performed simultaneously

---

7b. Cold Knife Conization (CKC)

• AIS (adenocarcinoma in situ)
• Suspected stage IA1 microinvasion
• Recurrent CIN after LEEP
• TZ 3 with high-grade pathology
• Discordant cytology-histology (very high cytologic grade)
• Positive ECC with high-grade histology

---

7c. Laser Conization

• Failure rate lower than LEEP (OR 0.59 vs. LEEP)
• Preterm birth OR 1.77 vs. untreated
• Limited availability; best for large lesions where precise depth control matters
• Can combine with laser ablation of edges for broader TZ coverage

---

7d. Cryotherapy

• WHO recommends for LMIC settings (screen-and-treat programs)
• Effective for small ectocervical lesions covering <75% of ectocervix
• Requires 2 freeze-thaw cycles (3 min / 5 min / 3 min)
• Failure rate significantly higher than LEEP (OR 1.84)
• Not recommended for CIN 3, large lesions, or TZ extending into canal

---

7e. CO₂ Laser Ablation

• Cure rate 90-95% for CIN 2/3
• Higher failure rate than LEEP (OR 1.69) and both conization techniques
• Maintains fertility potential (no preterm birth increase)
• Best reserved for selected small CIN 2 in women desiring future pregnancy who meet all ablation criteria

---

7f. Cold Coagulation (Semm)

• Thermal probe at 100-120°C for 20-30 seconds
• Network meta-analysis shows no significant difference vs. LEEP (OR 1.09, CI 0.68-1.74)
• No preterm birth increase
• Limited RCT data (only 2 small studies)
• Widely used in UK; cheap; outpatient

---

7g. Hysterectomy

1. Histologically confirmed recurrent high-grade CIN after multiple excisions
2. AIS with positive cone margins and completed childbearing
3. Microinvasion (FIGO stage IA1 without LVSI - simple hysterectomy)
4. Co-occurring gynecologic pathology requiring hysterectomy (fibroids, prolapse, endometriosis)

"Hysterectomy is the treatment of last resort for recurrent high-grade CIN." - Berek & Novak's Gynecology, p. 865

---

8. SPECIAL POPULATIONS

Table 4: Modified Management in Special Populations

---

9. POST-TREATMENT SURVEILLANCE

Table 5: Post-Treatment Follow-Up Protocol

• Positive surgical margins (most significant)
• Persistent HR-HPV post-treatment (especially HPV 16/18)
• Endocervical gland involvement
• CIN 3 (vs. CIN 2)
• Immunosuppression

---

10. EMERGING AND ADJUNCTIVE THERAPIES

Table 6: Emerging Treatment Options

---

11. 2024-2025 BIOMARKER ADVANCES: TRIAGE & RISK STRATIFICATION

Table 7: Molecular Markers in CIN Management

---

12. ADENOCARCINOMA IN SITU (AIS) - SPECIAL CONSIDERATION

---

13. SUMMARY MANAGEMENT TABLE

Table 8: At-a-Glance Management by Grade, Setting, and Special Circumstance

---

14. KEY CLINICAL PEARLS FOR THE GYNECOLOGIC ONCOLOGIST

1. "See and treat" is acceptable for HSIL cytology with colposcopic impression of CIN 2/3 in non-pregnant women - reduces loss to follow-up but risks overtreatment.
2. Margin status alone should not mandate immediate re-treatment after LEEP. HPV co-testing at 4-6 months is the preferred first step; colposcopy if co-test positive.
3. CIN 2 is a heterogeneous category: p16 IHC helps distinguish true high-grade lesion (CIN 3-equivalent) from CIN 1 with sampling artifact. p16-negative CIN 2 has much higher regression rate.
4. Adjuvant HPV vaccination reduces recurrence after excisional treatment: meta-analysis 2026 (PMID 41821885) confirms benefit regardless of timing (pre- or post-surgery) and vaccine valency, particularly for 9-valent vaccine. ASCCP formally recommends it (December 2025).
5. Extended genotyping changes management: HPV 16 + HSIL cytology now warrants "treatment preferred" without waiting for colposcopy biopsy confirmation (ASCCP 2025).
6. HPV persistence after treatment is the strongest recurrence predictor: HR-HPV positive at 6 months post-LEEP predicts CIN 2+ recurrence better than margin status.
7. Cryotherapy is NOT appropriate for: TZ 3, lesion >75% ectocervix, ECC positive, prior treatment failure, any CIN 3 extending to os, or AIS.
8. Long-term follow-up is mandatory: Women treated for CIN 2/3 have elevated cervical cancer risk for ≥20 years compared to the general population - co-testing for at least 20 years post-treatment is recommended.
9. LEEP in a future pregnancy: Preterm birth risk is dose-dependent on cone depth. Depth <10 mm has minimal risk; depth >20 mm significantly increases preterm birth rate.
10. Dual Stain (p16/Ki-67): HPV+ / DS- women can safely return to 1-year repeat HPV testing instead of immediate colposcopy, reducing unnecessary procedures by up to 40%.

---

Sources & Evidence Base

• Berek & Novak's Gynecology (p. 832-870) - Comprehensive CIN chapter
• Creasy & Resnik's Maternal-Fetal Medicine (p. 1351) - CIN in pregnancy
• Pfenninger & Fowler's Procedures for Primary Care - Histologic management algorithms
• Athanasiou et al., Lancet Oncol 2022 (PMID 35835138) - Network meta-analysis, 19,240 patients: comparative treatment failure and preterm birth rates
• Massad et al., J Low Genit Tract Dis 2025 (PMID 39791481) - ASCCP Extended Genotyping Enduring Guidelines
• Maiorano et al., Front Oncol 2026 (PMID 41821885) - HPV vaccine post-conization, meta-analysis
• Kapp et al., Cochrane 2025 (PMID 40919695) - Cochrane review: HPV vaccination post-conization
• Bomans et al., Obstet Gynecol 2025 (PMID 40638922) - Predictors of treatment failure post-excision, meta-analysis
• Reuschenbach et al., Eur J Obstet Gynecol 2024 (PMID 39002399) - Treatment characteristics and subsequent disease in high-grade CIN, European systematic review
• Sheth et al., Clin Cancer Res 2024 (PMID 38592381) - Phase II RCT: Imiquimod ± HPV vaccine for CIN 2/3
• ASCCP 2019 Risk-Based Management Consensus Guidelines (updated through 2025)
• USPSTF 2024 Draft Recommendation: Primary HPV screening preferred age 30-65